BOARD OF DIRECTORS

James S. Kuo, MD, MBA
Chairman of the Board

James S. Kuo, MD, MBA, is the Chairman and Chief Executive Officer of Duska Therapeutics, Inc., a public biopharmaceutical company. Dr. Kuo has been a founder, Chairman, and Chief Executive Officer of BioMicro Systems, Inc., a private venture-backed, microfluidics company. Prior to that time, Dr. Kuo was a founder, President, and Chief Executive Officer of Discovery Laboratories, Inc., where he raised over $22 million in initial private funding and took the company public. He further has been a founder and a Board Director of Monarch Labs, LLC, a private medical device company.

Dr. Kuo is the former Managing Director of Venture Analysis for HealthCare Ventures, LLC, which managed $378 million in venture funds. He has also been a senior licensing and business development executive at Pfizer, Inc., where he was directly responsible for cardiovascular licensing and development.

After studying molecular biology and receiving his B.A. at Haverford College, Dr. Kuo simultaneously received his M.D. from The University of Pennsylvania School of Medicine and his MBA from The Wharton School of Business at the University of Pennsylvania.

Christopher J. Schaber, PhD
President and Chief Executive Officer

Dr. Schaber has been our President and Chief Executive Officer and a director since August 2006. Prior to joining, Dr. Schaber served from 1998 to 2006 as Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc. where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research, and medical affairs, as well as coordination of commercial launch preparation activities. During his tenure at Discovery, Dr. Schaber played a significant role in raising in excess of $150 million through both public offerings and private placements. From 1996 to 1998, Dr. Schaber was a co-founder of Acute Therapeutics, Inc., and served as Vice President of Regulatory Compliance and Drug Development. From 1994 to 1996, Dr. Schaber was employed by Ohmeda PPD, Inc., as Worldwide Director of Regulatory Affairs and Operations. From 1989 to 1994, Dr. Schaber held a variety of regulatory, development and operations positions with The Liposome Company, Inc., and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories. Dr. Schaber received his B.A. from Western Maryland College, a M.S. in Pharmaceutics from Temple University School of Pharmacy and a PhD in Pharmaceutical Sciences from The Union Graduate School.

Evan Myrianthopoulos
Chief Financial Officer

Mr. Evan Myrianthopoulos has been a director of DOR since 2002 and is currently the chief financial officer (CFO) after joining the Company in November 2004 as president and acting CEO. From November 2001 to November 2004, Evan was president and founder of CVL Advisors, Group, Inc., a financial consulting firm specializing in the biotechnology sector. Prior to founding CVL Advisors Group, Inc., Mr. Myrianthopoulos was a co-founder of Discovery Laboratories. During his tenure at Discovery from June 1996 to November 2001, Mr. Myrianthopoulos held the positions of CFO and vice president of finance, where he was responsible for raising approximately $55 million in four private placements. He also helped negotiate and manage Discovery’s mergers with Ansan Pharmaceuticals and Acute Therapeutics. Prior to co-founding Discovery, Mr. Myrianthopoulos was a technology associate at Paramount Capital Investments, LLC, a New York City-based biotechnology venture capital and investment banking firm. Prior to joining Paramount Capital, Mr. Myrianthopoulos was a managing partner at a hedge fund, and also held senior positions in the treasury department at the National Australia Bank where he was employed as a spot and derivatives currency trader. Mr. Myrianthopoulos holds a B.S. in economics and psychology from Emory University.

Cyrille Buhrman
Board Director

Mr. Buhrman is Managing Director, Chairman and owner of Pacific Healthcare ( Thailand ) Co., Ltd., a full service marketing, sales, distribution and regulatory affairs company based in Thailand where he has served for approximately ten years. Pacific Healthcare is currently expanding throughout Southeast Asia , starting with the Philippines and Vietnam this year. Mr. Buhrman is a Director of Pacific Healthcare ( Philippines ) Inc., International Pharmaceuticals Ltd., a company focused on marketing Specialty pharmaceutical products in Thailand , Vision Care ( Thailand ) Co., Ltd, and Canyon Pharmaceuticals, Inc., a private biotechnology company focused on the commercialization of therapeutics to prevent and treat thrombosis and related conditions. Mr. Buhrman is owner of Markle Holdings Ltd., an investment fund specializing in biotech and pharmaceutical investments. Mr. Buhrman is also one of DOR ’s largest shareholders.